The gyrA genes isolated from three ciprofloxacin-resistant clinical isolates of Staphylococcus aureus carried codon 84 (serine-leucine) and/or codon 85 (serine-*proline) mutations that were absent in pretreatment susceptible strains. These substitutions occur in a region of the gyrase A protein wherein directly analogous mutations of serine 83-*leucine and alanine 84->proline in Escherichia coli confer quinolone resistance. Thus, DNA gyrase A subunit mutations are implicated in resistance to ciprofloxacin in S. aureus.
The gyrA genes isolated from three ciprofloxacin-resistant clinical isolates of Staphylococcus aureus carried codon 84 (serine-leucine) and/or codon 85 (serine-*proline) mutations that were absent in pretreatment susceptible strains. These substitutions occur in a region of the gyrase A protein wherein directly analogous mutations of serine 83-*leucine and alanine 84->proline in Escherichia coli confer quinolone resistance. Thus, DNA gyrase A subunit mutations are implicated in resistance to ciprofloxacin in S. aureus.
Fluoroquinolone inhibitors of DNA gyrase (e.g., ciprofloxacin) are potent antibacterial agents that have been widely used in the treatment of difficult bacterial infections, including those involving methicillin-resistant Staphylococcus aureus strains (10, 14, 18) . However, similar to experience with earlier quinolones such as nalidixic acid, the isolation of S. aureus strains resistant to fluoroquinolones is now commonplace (8, 11, 12 Med., in press). The emergence of fluoroquinolone resistance is of particular concern given that relatively few antimicrobial agents are effective against methicillin-resistant staphylococcal infections.
The molecular basis of quinolone resistance in S. aureus is not understood. In Escherichia coli, resistance commonly arises through mutation of the gyrA and (less often) gyrB genes, encoding the A and B subunits of the A2B2 gyrase complex which catalyzes ATP-dependent DNA supercoiling (references 3, 4, and 19 to 21 and references therein). Analysis of the S. aureus gyrB-gyrA locus, recently isolated from ciprofloxacin-susceptible clinical isolate 81231, revealed that the N-terminal region of the S. aureus gyrase A subunit is highly homologous to that of its E. coli counterpart (6) . In particular, Ala-67, Ser-83, and Gln-106, residues whose substitution leads to quinolone resistance in E. coli (1, 2, 20, 21; our unpublished data), are all conserved in the S. aureus gyrase A protein as residues 68, 84, and 107 (6) . This observation led us to examine whether ciprofloxacin resistance in S. aureus is associated with mutations similar to those found in E. coli.
We (2) shows that any mutation that removes this Hinfl site will necessarily cause an amino acid substitution in the gyrase A protein either at position 83 or at position 84. To detect polymorphism at the 247 Hinfl site, genomic DNA was isolated from clinical isolates (9), digested with Hinfl, and hybridized on Southern blots to an RsaI-ClaI gyrA probe (nucleotide positions 271 to 439) (Fig.  la) . The presence or absence of the 247 site should result in the detection of a 241-or 430-bp Hinfl fragment, respectively ( Fig. la) . In this assay, Hybond-N filters were hybridized overnight at 650C in 5x SSC (SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 1.5% dried milk. Filters were washed successively in 2x SSC-0. 1% sodium dodecyl sulfate (SDS) (two 10-min washes at room temperature), then in lx SSC-0.1% SDS (two washes as before), and finally in O.lx SSC-0.1% SDS (two 15-min washes at 650C). DNAs from ciprofloxacin-susceptible strains 34, 31, and 42 gave the smaller 241-bp fragment (Fig. lb) (81231)
CAT GGT GAC TCA TCT ATT TAT GAA GCA ATG GTA 34 (s) (Fig. 2) . The gyrA gene fragments obtained from ciprofloxacinsusceptible isolates 34, 31, and 42 were identical in sequence to that reported previously for gyrA in S. aureus 81231 ( Fig.   2 ) (6). DNA sequences obtained for resistant isolates 35 and 47 were identical to that for strain 81231 gyrA except for single-base changes: a T-*C transition in strain 35 gyrA (nucleotide 253), producing a Ser-85-*Pro substitution in the gyrase A protein, and a C-*T transition in strain 47 gyrA (position 251), resulting in a Ser-84--*Leu substitution at the protein level. Interestingly, resistant isolate 146 carried both of these gyrA mutations. Since only the Ser-84--Leu codon change abolishes the 247 Hinfl site (Fig. 2) , the DNA sequence results are in accord with those of the RFLP analysis (Fig. 1) .
Two lines of evidence strongly suggest that the gyrA mutations reported here are responsible for or at least contribute to ciprofloxacin resistance in S. aureus. First, the Ser-85-->Pro and Ser-84--Leu changes were present in the gyrase A protein of resistant S. aureus strains isolated posttherapy but were absent in the corresponding susceptible pretreatment isolates (Table 1 and Fig. 2 (17) . The norA gene has a restriction map different from that of our S. aureus gyrase clones and unlike resistant gyrase genes appears to act in a genetically dominant fashion (5, 17) . The data suggest that norA is not a gyrase allele.
Understanding the mechanism by which quinolone resistance mutations act on DNA gyrase has been hindered by the absence of structural information on the drug-gyrase-DNA complex. However, Shen and colleagues have proposed a model in which the quinolone binds both to gyrase and to the single-stranded DNA regions resulting from transient DNA breakage by the A subunits (13) . Mutation of specific gyrase A residues close to catalytic Tyr-122 (7) (e.g., Ser-83 [84 in S. aureus] to hydrophobic residue Leu or Trp) presumably disrupts key interactions involving the gyrasequinolone complex. Although highly conserved, gyrase A proteins from different species also exhibit sequence differences that may modulate quinolone action. For example, S. aureus gyrase A protein has the sequence Asp-Ser-Ser at positions 83 to 85 instead of the Asp-Ser-Ala in E. coli (Fig.  2) . Interestingly, we find that substitution of Ser-85 with proline, which could produce a major structural alteration, is also associated with high-level ciprofloxacin resistance in S. aureus. It may be that serine in the S. aureus A protein either preserves or can take part in a critical interaction necessary for quinolone action. Such considerations will be important in assessing the different quinolone sensitivities of DNA gyrases from different susceptible and resistant bacterial sources (16 
